To this end, HLA-I down-regulation has been noted as a possible mechanism for anti-PD-1 therapy resistance, according to a previous study regarding malignant melanoma.13 However, the relationship between expression of HLA-I and PD-L1, and tumour immunity has not been fully understood, especially in GC. This evidence concerns the gene CD274 and neoplasm.